Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

Daveen Chopra Biography and Net Worth

VP of Edwards Lifesciences

Daveen Chopra has been corporate vice president, Surgical Structural Heart since May 2018. Chopra has broad experience in the medical technology industry, including global leadership in strategy, marketing, commercial operations, research and development, and program management. Prior to joining Edwards, Chopra held various roles with increasing levels of responsibility at Medtronic, plc, from 2005 to 2018, culminating in a global leadership role as vice president and general manager of its aortic franchise. Chopra previously served as vice president of global marketing leading Medtronic’s endovascular therapies business. While in Medtronic’s endovascular therapies business, he served as vice president, U.S. commercial operations, director of program management office, senior business manager for the endovascular and peripheral business in Asia-Pacific, global group product manager for thoracic stent grafts, and international aortic product manager. Prior to Medtronic, Chopra served as an international strategy consultant at The Parthenon Group supporting clients in various industries ranging from education to industrial manufacturing. In 2020, he joined the board of the Edwards Lifesciences Foundation, and, in 2021, he joined the board of Octane. Chopra earned a dual bachelor’s degree in economics and biology from Duke University, and a masters from Harvard Business School, where he graduated with honors.

What is Daveen Chopra's net worth?: The estimated net worth of Daveen Chopra is at least $2.00 million as of February 21st, 2024. Mr. Chopra owns 22,750 shares of Edwards Lifesciences stock worth more than $1,995,858 as of April 24th. This net worth estimate does not reflect any other assets that Mr. Chopra may own. Learn More about Daveen Chopra's net worth.
How do I contact Daveen Chopra?: The corporate mailing address for Mr. Chopra and other Edwards Lifesciences executives is ONE EDWARDS WAY, IRVINE CA, 92614. Edwards Lifesciences can also be reached via phone at (949) 250-2500 and via email at [email protected]. Learn More on Daveen Chopra's contact information.
Has Daveen Chopra been buying or selling shares of Edwards Lifesciences?: Daveen Chopra has not been actively trading shares of Edwards Lifesciences in the last ninety days. Most recently, Daveen Chopra sold 8,200 shares of the business's stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $86.74, for a transaction totalling $711,268.00. Following the completion of the sale, the vice president now directly owns 22,750 shares of the company's stock, valued at $1,973,335. Learn More on Daveen Chopra's trading history.
Who are Edwards Lifesciences' active insiders?: Edwards Lifesciences' insider roster includes Donald Bobo, Jr (VP), Daveen Chopra (VP), Kieran Gallahue (Director), Leslie Heisz (Director), Jean-Luc Lemercier (VP), Martha Marsh (Director), Michael Mussallem (CEO), Robert Sellers (VP), Catherine Szyman (VP), Scott Ullem (CFO), Nicholas Valeriani (Director), Huimin Wang (VP), Larry Wood (VP), and Bernard Zovighian (VP). Learn More on Edwards Lifesciences' active insiders.
Are insiders buying or selling shares of Edwards Lifesciences?: In the last year, insiders at the medical research company sold shares 60 times. They sold a total of 768,312 shares worth more than $62,771,727.15. The most recent insider tranaction occured on April, 8th when VP Jean-Luc M Lemercier sold 14,400 shares worth more than $1,329,408.00. Insiders at Edwards Lifesciences own 1.3% of the company. Learn More about insider trades at Edwards Lifesciences.
Information on this page was last updated on 4/8/2024.

Daveen Chopra Insider Trading History at Edwards Lifesciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/21/2024	Sell	8,200	$86.74	$711,268.00	22,750
12/15/2023	Sell	7,000	$78.25	$547,750.00	23,950
12/6/2023	Sell	3,500	$70.00	$245,000.00	23,950
10/3/2023	Sell	8,500	$70.00	$595,000.00	23,950
9/6/2023	Sell	8,500	$76.07	$646,595.00	23,950
8/29/2023	Sell	1,500	$76.69	$115,035.00	23,950
3/15/2023	Sell	4,435	$77.47	$343,579.45	18,911
2/15/2023	Sell	4,000	$76.01	$304,040.00	18,911
1/17/2023	Sell	4,000	$78.00	$312,000.00	18,911
12/15/2022	Sell	4,000	$74.80	$299,200.00	18,911
11/15/2022	Sell	4,000	$74.18	$296,720.00	18,911
10/14/2022	Sell	4,000	$84.77	$339,080.00	18,911
8/2/2022	Sell	1,000	$102.49	$102,490.00	18,911
5/26/2022	Sell	1,000	$98.31	$98,310.00	19,911

Daveen Chopra Buying and Selling Activity at Edwards Lifesciences

Edwards Lifesciences Company Overview

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Today's Range

Now: $87.73

$86.76

$87.92

50 Day Range

MA: $90.18

$84.87

$95.56

2 Week Range

Now: $87.73

$60.57

$96.12

Volume

2,663,641 shs

Average Volume

3,831,539 shs

Market Capitalization

$52.81 billion

P/E Ratio

38.14

Dividend Yield

N/A

Beta

1.05

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

From Traders Agency | Ad

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…